These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29561434)

  • 1. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
    Cao Z; Wei L; Zhu W; Yao X
    Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse association of p16 INK4a and p14 ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer.
    Verdoodt B; Sommerer F; Palisaar RJ; Noldus J; Vogt M; Nambiar S; Tannapfel A; Mirmohammadsadegh A; Neid M
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):295-301. PubMed ID: 21912429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers.
    Nguyen TT; Nguyen CT; Gonzales FA; Nichols PW; Yu MC; Jones PA
    Prostate; 2000 May; 43(3):233-42. PubMed ID: 10797499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
    Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and prognostic effects of
    Xia L; Zhang W; Gao L
    Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
    [No Abstract]   [Full Text] [Related]  

  • 7. A quantitative promoter methylation profile of prostate cancer.
    Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Retinoic Acid Receptor Beta Promoter Methylation in Prostate Cancer: A Meta-Analysis.
    Dou M; Zhou X; Fan Z; Ding X; Li L; Wang S; Xue W; Wang H; Suo Z; Deng X
    Cell Physiol Biochem; 2018; 45(6):2497-2505. PubMed ID: 29554659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
    Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
    Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma.
    Ben-Dayan MM; Ow TJ; Belbin TJ; Wetzler J; Smith RV; Childs G; Diergaarde B; Hayes DN; Grandis JR; Prystowsky MB; Schlecht NF
    Cancer Med; 2017 Feb; 6(2):397-407. PubMed ID: 28102032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.
    Sinha S; Chunder N; Mukherjee N; Alam N; Roy A; Roychoudhury S; Kumar Panda C
    Ann Surg Oncol; 2008 Apr; 15(4):1070-80. PubMed ID: 18239974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.
    Lim AM; Do H; Young RJ; Wong SQ; Angel C; Collins M; Takano EA; Corry J; Wiesenfeld D; Kleid S; Sigston E; Lyons B; Fox SB; Rischin D; Dobrovic A; Solomon B
    Int J Cancer; 2014 Aug; 135(4):887-95. PubMed ID: 24436120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
    Spitzwieser M; Entfellner E; Werner B; Pulverer W; Pfeiler G; Hacker S; Cichna-Markl M
    BMC Cancer; 2017 Apr; 17(1):260. PubMed ID: 28403857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
    Zhou Y; Wang XB; Qiu XP; Shuai Zhang ; Wang C; Zheng F
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):529-541. PubMed ID: 30143452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression.
    Hu Y; Wu Q; Gao J; Zhang Y; Wang Y
    BMC Urol; 2019 Jul; 19(1):67. PubMed ID: 31324239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of hypermethylation of p16 gene in esophageal cancer.
    Xu R; Wang F; Wu L; Wang J; Lu C
    Cancer Biomark; 2013; 13(4):215-26. PubMed ID: 24240582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry.
    Yang B; Sun H; Lin W; Hou W; Li H; Zhang L; Li F; Gu Y; Song Y; Li Q; Zhang F
    Urol Oncol; 2013 Jul; 31(5):628-34. PubMed ID: 21704537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications.
    Jiao Y; Feng Y; Wang X
    Biochemistry (Mosc); 2018 Nov; 83(11):1289-1298. PubMed ID: 30482142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.